CD274 and small cell lung carcinoma: To the best of our knowledge, this study is the first to report the use of first-line anti-PD-L1 ICIs (atezolizumab and durvalumab) combined with standard chemotherapy for the treatment of extensive SCLC in real-world clinical practice.